Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + Atezolizumab in NSCLC with Brain Metastases
NCT05746481Phase 2Terminated
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in non-small cell lung cancer (NSCLC). Started Aug 2023; status: terminated.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05746481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746481.